RecruitingNot ApplicableNCT07121140

Home Blood Transfusions

A Pilot Study of Home Blood Transfusions for Patient With Cancer Who Have Transfusion Dependent Cytopenias

Sponsor

Thomas Jefferson University

Enrollment

30 participants

Start Date

Jun 3, 2025

Study Type

INTERVENTIONAL

Conditions

Acute Myeloid Leukemia Hematologic Malignancy Myelodysplastic Syndromes Transfusion Dependent Cytopenias

Summary

This is a pilot single arm study to evaluate the feasibility and acceptability of a home blood transfusion program. Patients will be enrolled with hematologic malignancies and other bone marrow failure syndromes who are transfusion dependent and interested in a home blood transfusion program. Participants enrolled in the study will receive 1-5 units of blood products at home. Data on barriers to administration will be recorded. Surveys and qualitative interviews will be completed to better understand acceptability of the program.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether blood transfusions can be safely and effectively given at home to cancer patients who need them regularly. Many patients require frequent transfusions and currently must travel to a clinic or hospital each time. This trial explores whether home-based transfusions are a viable option that could improve quality of life. **You may be eligible if...** - You are 18 or older and receive your cancer care at the Sidney Kimmel Comprehensive Cancer Center (SKCCC) - You are transfusion-dependent, meaning you need at least 2 blood transfusions within any 28-day period - You have a history of receiving blood products without complications - You are willing to comply with all study procedures **You may NOT be eligible if...** - You have had serious transfusion reactions in the past - You are not receiving cancer care at SKCCC - You are unable to safely receive transfusions outside a hospital setting - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREHome Blood Transfusion

Participants will be provided with transfusion of blood products, specifically red blood cells and platelets, in the home setting.

Locations(1)

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07121140

Related Trials

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390346 locations

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

NCT063031931 location

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT0532019824 locations

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT05554393177 locations

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT05554406220 locations